RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
RBC Capital has reiterated its Buy rating on Damora Therapeutics (DMRA.US), maintaining a target price of $40. This indicates a continued positive outlook from the firm regarding the company's stock performance.